Table 2 Demographic characteristics of study subjects
| Â | Piperacillin/tazobactam (NÂ =Â 33) | Cefepime (NÂ =Â 6) | Ertapenem (NÂ =Â 33) | p-value |
|---|---|---|---|---|
Age | 68.8 ± 14.4 | 75.3 ± 6.6 | 65.2 ± 16.9 | 0.281 |
Female | 30 (90.9) | 3 (50.0) | 26 (78.8) | 0.049 |
Comorbidity, n (%) | ||||
 Ischemic heart disease | 0 (0) | 0 (0) | 1 (3.0) | 1.000 |
 Diabetes mellitus | 12 (36.4) | 1 (16.7) | 15 (45.5) | 0.474 |
 Cerebrovascular accident | 5 (15.2) | 1 (16.7) | 2 (6.1) | 0.420 |
 Dementia | 3 (9.1) | 0 (0) | 2 (6.1) | 1.000 |
 Hemiplegia | 2 (6.1) | 0 (0) | 2 (6.1) | 1.000 |
 Congestive heart failure | 5 (15.2) | 1 (16.7) | 1 (3.0) | 0.230 |
 COPD | 1 (3.0) | 0 (0) | 1 (3.0) | 1.000 |
 Chronic kidney disease | 2 (6.1) | 0 (0) | 2 (6.1) | 1.000 |
 Liver cirrhosis | 2 (6.1) | 0 (0) | 4 (12.1) | 0.809 |
 Solid tumor | 6 (18.2) | 1 (16.7) | 7 (21.2) | 1.000 |
 Lymphoma | 1 (3.0) | 0 (0) | 2 (6.1) | 1.000 |
 None | 12 (36.4) | 2 (33.3) | 12 (36.4) | 1.000 |
Charlson comorbidity index | 4.7 ± 3.0 | 4.7 ± 1.0 | 4.5 ± 3.0 | 0.951 |
Bacteremia, n (%) | 9 (27.3) | 0 (0) | 7 (21.2) | 0.477 |
Septic shock, n (%) | 9 (24.2) | 2 (33.3) | 11 (33.3) | 0.928 |
APACH II score | 12.9 ± 2.9 | 16.5 ± 6.4 | 16.6 ± 5.6 | 0.298 |